Reply: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy
Hepatology
.
2024 Apr 1;79(4):E125-E126.
doi: 10.1097/HEP.0000000000000738.
Epub 2023 Dec 26.
Authors
Daniel J Zabransky
1
,
Mark Yarchoan
1
2
,
Won Jin Ho
1
2
3
Affiliations
1
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
2
The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
3
Flow/Mass Cytometry Facility, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
PMID:
38147327
DOI:
10.1097/HEP.0000000000000738
No abstract available
MeSH terms
Carcinoma, Hepatocellular* / drug therapy
Carcinoma, Hepatocellular* / pathology
Cell Line, Tumor
Humans
Liver Neoplasms* / drug therapy
Liver Neoplasms* / pathology